MedPath

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Leukemia
Registration Number
NCT00009698
Lead Sponsor
Children's Oncology Group
Brief Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill more cancer cells.

PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating children who have undergone bone marrow transplantation for acute myeloid leukemia.

Detailed Description

OBJECTIVES: I. Determine the maximum tolerated dose of interleukin-2 after autologous bone marrow transplantation in pediatric patients with acute myeloid leukemia. II. Determine toxic effects of this regimen in these patients.

OUTLINE: This is a dose escalation study. Patients receive interleukin-2 (IL-2) subcutaneously on days 1-7, 9-14, and 16-22. On days 8 and 15, patients receive IL-2 IV over 2 hours. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 6-9 patients receive escalating doses of IL-2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 2 of 9 patients experience dose-limiting toxicity. Patients are followed every 6 months for 4 years and then annually thereafter.

PROJECTED ACCRUAL: A total of 6-27 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
To determine the maximum tolerated dose (MTD) of IL-22 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (119)

University of Alabama at Birmingham Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Birmingham, Alabama, United States

University of South Alabama Medical Center

πŸ‡ΊπŸ‡Έ

Mobile, Alabama, United States

MBCCOP - Gulf Coast

πŸ‡ΊπŸ‡Έ

Mobile, Alabama, United States

Arizona Cancer Center

πŸ‡ΊπŸ‡Έ

Tucson, Arizona, United States

Arkansas Children's Hospital

πŸ‡ΊπŸ‡Έ

Little Rock, Arkansas, United States

University of Arkansas for Medical Sciences

πŸ‡ΊπŸ‡Έ

Little Rock, Arkansas, United States

University of California San Diego Cancer Center

πŸ‡ΊπŸ‡Έ

La Jolla, California, United States

Lucile Packard Children's Hospital at Stanford

πŸ‡ΊπŸ‡Έ

Palo Alto, California, United States

Sutter Cancer Center

πŸ‡ΊπŸ‡Έ

Sacramento, California, United States

University of California Davis Medical Center

πŸ‡ΊπŸ‡Έ

Sacramento, California, United States

Scroll for more (109 remaining)
University of Alabama at Birmingham Comprehensive Cancer Center
πŸ‡ΊπŸ‡ΈBirmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.